{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:37:24Z","timestamp":1780609044015,"version":"3.54.1"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3609,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2002,3]]},"abstract":"<jats:p>Pericarditis should be considered in any patient complaining of chest pain and\/or dyspnea who is taking a product that contains mesalamine or sulfasalazine. A 41\u2010year\u2010old woman was taking mesalamine 800 mg 3 times\/day for 3 weeks before hospital admission. She complained of sharp, pleuritic chest pain that radiated down both arms and increased in intensity when lying down. She was diagnosed with pericarditis based on clinical presentation and electrocardiogram findings. Differential diagnoses for myocardial infarction, systemic lupus erythematosus, and viral or bacterial causes were ruled out based on subjective and objective data. Mesalamine\u2010induced pericarditis was considered on hospital day 2, and the drug was discontinued at discharge on day 3. Clinicians should be aware of this potential drug\u2010related complication, as the relationship between mesalamine or sulfasalazine and pericarditis has been reported rarely in the literature.<\/jats:p>","DOI":"10.1592\/phco.22.5.391.33188","type":"journal-article","created":{"date-parts":[[2004,5,21]],"date-time":"2004-05-21T09:33:50Z","timestamp":1085132030000},"page":"391-394","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Possible Mesalamine\u2010Induced Pericarditis: Case Report and Literature Review"],"prefix":"10.1002","volume":"22","author":[{"given":"Robert A.","family":"Waite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Malinowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","volume-title":"Gastrointestinal and liver disease: pathophysiology\/diagnosis\/management","author":"Feldman M.","year":"1998"},{"key":"e_1_2_1_3_2","volume-title":"Harrison's principles of internal medicine","author":"Braunwald E.","year":"2001"},{"key":"e_1_2_1_4_2","volume-title":"Meyler's side effects of drugs","author":"Dukes M.N.G.","year":"2000"},{"key":"e_1_2_1_5_2","volume-title":"Davies's textbook of adverse drug reactions","author":"Davies D.M.","year":"1998"},{"key":"e_1_2_1_6_2","unstructured":"Procter & Gamble Pharmaceuticals.Asacol (mesalamine) product information. Available fromhttp:www.asacol.com. Accessed July 29 2001."},{"key":"e_1_2_1_7_2","volume-title":"Pentasa (mesalamine) package insert","author":"Roberts Pharmaceuticals.","year":"1999"},{"key":"e_1_2_1_8_2","volume-title":"Rowasa (mesalamine) package insert","author":"Solvay Pharmaceuticals.","year":"1998"},{"key":"e_1_2_1_9_2","volume-title":"Canasa (mesalamine) product information","author":"Axcan Scandipharm Inc.","year":"2001"},{"key":"e_1_2_1_10_2","volume-title":"Drug facts and comparisons","year":"2002"},{"key":"e_1_2_1_11_2","volume-title":"AHFS drug information","author":"McEnvoy G.K.","year":"2001"},{"key":"e_1_2_1_12_2","volume-title":"DRUGDEX system","author":"Hutchinson T.A.","year":"2001"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1536-4801.1997.tb01785.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1536-4801.1998.tb01267.x"},{"issue":"2","key":"e_1_2_1_15_2","first-page":"17","article-title":"Rare adverse reactions with Rowasa","volume":"19","author":"Food and Drug Administration.","year":"1989","journal-title":"FDA Drug Bull"},{"issue":"3","key":"e_1_2_1_16_2","first-page":"332","article-title":"Pericardial effusions during treatment with 5\u2010aminosalicylic acid in a patient with Crohn's disease","volume":"85","author":"Jenss H.","year":"1990","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6846.159-b"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6921.113"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02282352"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.22.5.391.33188","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.22.5.391.33188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:05:35Z","timestamp":1761059135000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.22.5.391.33188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["10.1592\/phco.22.5.391.33188"],"URL":"https:\/\/doi.org\/10.1592\/phco.22.5.391.33188","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}